文献速递泌尿生殖腹部CT

前列腺立体定向消融放疗中危及器官每日变化对剂量学的影响

Dosimetric impact of organ at risk daily variation during prostate stereotactic ablative radiotherapy.
PubMed 文献 · Br J Radiol · 2020-01-30

本研究纳入41例低中危前列腺癌患者,采用基于直线加速器的立体定向消融放疗(SABR),处方剂量35 Gy分5次隔日照射,计划用容积旋转调强放疗(VMAT)配合10X无均整器模式(FFF)。在205幅治疗前锥形束CT(CBCT)上回顾性勾画危及器官,比较每日实际剂量与计划剂量,发现直肠和膀胱在多数剂量水平上实际受照剂量高于计划。

要点

  • 前列腺SABR中直肠和膀胱每日实际受照剂量在多数剂量水平高于计划剂量。
  • 直肠剂量增加范围为0.78-1.64 Gy,膀胱剂量增加范围为0.14-1.07 Gy。
  • 直肠D35%<18 Gy、D10%<28 Gy、D5%<32 Gy、D1%<35 Gy及膀胱D1%<35 Gy的治疗失败率均具统计学显著性。

核心结论

  • 在该前列腺SABR队列中,危及器官的治疗剂量体积直方图(DVH)估计高于计划,归因于直肠和膀胱的器官变化。
  • 使用FFF技术的前列腺SABR中,危及器官变化可能导致治疗DVH高于计划。

研究设计与样本

  • 研究类型为回顾性剂量学分析,纳入41例低中危前列腺癌患者。
  • 采用基于直线加速器的SABR技术,处方剂量35 Gy分5次隔日照射,计划使用VMAT配合10X FFF。
  • 治疗时前列腺基于锥形束CT(CBCT)与基准标记配准,在205幅治疗前CBCT图像上回顾性勾画危及器官。
  • 将每日CBCT轮廓叠加至计划CT进行剂量学分析,使用验证计划评估各结构的每日DVH,以D%记录危及器官每日受照剂量。

诊断标准与关键数值

  • 计划时直肠中位体积为67.1 cm3(四分位距56.4-78.2),膀胱中位体积为164.4 cm3(四分位距120.3-213.4)。
  • 五次治疗扫描中直肠中位体积与计划扫描相比无统计学显著差异(p=0.99),膀胱中位体积亦无统计学显著差异(p=0.79)。
  • 直肠在多数剂量水平的每日中位受照剂量高于计划,增加范围为0.78-1.64 Gy;膀胱增加范围为0.14-1.07 Gy。
  • 治疗时直肠D35%<18 Gy(p=0.016)、D10%<28 Gy(p=0.004)、D5%<32 Gy(p=0.0001)、D1%<35 Gy(p=0.0001)及膀胱D1%<35 Gy(p=0.001)的患者失败率均具统计学显著性。

临床应用与阅片要点

  • 前列腺SABR中应关注直肠和膀胱每日体积变化对实际受照剂量的影响。
  • 基于CBCT的每日验证计划可用于评估危及器官每日DVH与计划DVH的差异。
  • 直肠D35%、D10%、D5%、D1%及膀胱D1%等剂量指标在治疗中可能超出计划约束,需在报告中关注。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Prostate stereotactic ablative radiotherapy (SABR) delivers large doses using a fast dose rate. This amplifies the effect geometric uncertainties have on normal tissue dose. The aim of this study was to determine whether the treatment dose-volume histogram (DVH) agrees with the planned dose to organs at risk (OAR).

METHODS: 41 low-intermediate risk prostate cancer patients were treated with SABR using a linac based technique. Dose prescribed was 35 Gy in five fractions delivered on alternate days, planned using volumetric modulated arc therapy (VMAT) with 10X flattening filter free (FFF). On treatment, prostate was matched to fiducial markers on cone beam CT (CBCT). OAR were retrospectively delineated on 205 pre-treatment CBCT images. Daily CBCT contours were overlaid on the planning CT for dosimetric analysis. Verification plan used to evaluate the daily DVH for each structure. The daily doses received by OAR were recorded using the D%.

RESULTS: The median rectum and bladder volumes at planning were 67.1 cm3 (interquartile range 56.4-78.2) and 164.4 cm3 (interquartile range 120.3-213.4) respectively. There was no statistically significant difference in median rectal volume at each of the five treatment scans compared to the planning scan (p = 0.99). This was also the case for median bladder volume (p = 0.79). The median dose received by rectum and bladder at each fraction was higher than planned, at the majority of dose levels. For rectum the increase ranged from 0.78-1.64Gy and for bladder 0.14-1.07Gy. The percentage of patients failing for rectum D35% < 18 Gy (p = 0.016), D10% < 28 Gy (p = 0.004), D5% < 32 Gy (p = 0.0001), D1% < 35 Gy (p = 0.0001) and bladder D1% < 35 Gy (p = 0.001) at treatment were all statistically significant.

CONCLUSION: In this cohort of prostate SABR patients, we estimate the OAR treatment DVH was higher than planned. This was due to rectal and bladder organ variation.

ADVANCES IN KNOWLEDGE: OAR variation in prostate SABR using a FFF technique, may cause the treatment DVH to be higher than planned.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Devlin L, Dodds D, Sadozye A, et al. Dosimetric impact of organ at risk daily variation during prostate stereotactic ablative radiotherapy. Br J Radiol. 2020. PMID: 31971829. doi:10.1259/bjr.20190789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。